Clinical Trial Update: LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib [Phase 3]

View source ↗

Summary

Phase 3 trial results for LUX-Lung 5 evaluating afatinib plus weekly paclitaxel versus investigator's choice chemotherapy after afatinib in non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2014-10-03